logo

Bioxcel Therapeutics, Inc. (BTAI)



Trade BTAI now with
  Date
  Headline
12/1/2021 7:37:02 AM BioXcel Therapeutics Extends FDA Review Period Of NDA For BXCL501 By Three Months To April 5, 2022
8/10/2021 7:30:15 AM BioXcel Therapeutics Q2 Net Loss Of $27.6 Mln Vs Loss Of $21.4 Mln Last Year
5/19/2021 7:26:20 AM BioXcel: FDA Accepts BXCL501 NDA Filing For Acute Treatment Of Agitation Associated With Schizophrenia& Bipolar Disorder
3/15/2021 7:12:35 AM BioXcel's BXCL501 Gets FDA Breakthrough Therapy Designation For Acute Treatment Of Agitation Associated With Dementia
3/11/2021 7:14:58 AM BioXcel Submits NDA For BXCL501 For Acute Treatment Of Agitation Associated With Schizophrenia And Bipolar Disorders
1/5/2021 7:13:48 AM BioXcel Says BXCL501 Meets Endpoints In TRANQUILITY Phase 1b/2 Study For Acute Treatment Of Agitation In Dementia
11/11/2020 7:17:15 AM BioXcel Therapeutics Completes Pre-NDA Meeting With FDA For BXCL501
10/26/2020 7:15:08 AM BioXcel Therapeutics Gets FDA Clearance Of IND For Phase 2 Trial With BXCL501 For Agitation Associated With Delirium
8/14/2020 7:15:43 AM BioXcel Therapeutics Q2 Net Loss Of $21.4 Mln Opr$1.06/Shr Vs Loss $8.47 Mln Or $0.54/Shr Last Year
7/20/2020 7:10:35 AM BioXcel Therapeutics Announces Primary And Secondary Endpoints Met In Two SERENITY Trials
7/9/2020 7:21:16 AM BioXcel Announces Compassionate Use Program At Massachusetts General Hospital For BXCL501
7/7/2020 7:23:41 AM BioXcel Therapeutics Gets Notice Of Allowance For U.S. Patent Application Covering Formulation For BXCL501
6/23/2020 7:14:31 AM BioXcel Therapeutics Appoints Reina Benabou As Chief Development Officer